Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam.

about

Modeling Drug Disposition and Drug-Drug Interactions Through Hypothesis-Driven Physiologically Based Pharmacokinetics: a Reversal Translation Perspective.

P2860

Q50076374-2DDAFAE5-ABCC-499B-8051-5BC482D5068E

P2860

Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam.

Item

http://www.wikidata.org/entity/Q47628234

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Physiologically Based Pharmaco ...... Sulfaphenazole and Tasisulam.

@en

Physiologically Based Pharmaco ...... Sulfaphenazole and Tasisulam.

@nl

type

Item

label

Physiologically Based Pharmaco ...... Sulfaphenazole and Tasisulam.

@en

Physiologically Based Pharmaco ...... Sulfaphenazole and Tasisulam.

@nl

prefLabel

Physiologically Based Pharmaco ...... Sulfaphenazole and Tasisulam.

@en

Physiologically Based Pharmaco ...... Sulfaphenazole and Tasisulam.

@nl

P1476

Physiologically Based Pharmaco ...... h Sulfaphenazole and Tasisulam

@en

P2093

Chris Twelves

http://www.w3.org/2001/XMLSchema#string

Jill Chappell

http://www.w3.org/2001/XMLSchema#string

Maria Posada

http://www.w3.org/2001/XMLSchema#string

P Kellie Turner

http://www.w3.org/2001/XMLSchema#string

Wee Teck Ng

http://www.w3.org/2001/XMLSchema#string

P2860

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P-450

Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.

Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes.

Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.

Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.

A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.

A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.

Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study.

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.

P2888

s13318-017-0447-5

P304

355-367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13318-017-0447-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Everett J Perkins

P577

2018-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29119333

http://www.w3.org/2001/XMLSchema#string

P932

5956062

http://www.w3.org/2001/XMLSchema#string

Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam.

about

P2860

P2860

Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932